Acute coronary syndrome after infliximab infusion.
The TNFalpha inhibitor infliximab is widely used in the treatment of rheumatoid arthritis and Crohn disease. Mild infusion reactions consisting of low-grade fever, headache, nausea, and fatigue are common, but we describe for the first time the occurrence of an acute coronary syndrome during infliximab administration. This case alerts infusion centers to consider the possibility that chest pain and dyspnea during infliximab infusion can represent a myocardial infarction, even in younger patients without a history of cardiac disease.
Abedin
Moeen
M
Cardiology Division, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8884, USA.
Scheurich
Daniel
D
Reimold
Sharon C
SC
Reimold
Andreas M
AM
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006328:Cardiac Catheterization; D003327:Coronary Disease / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008875:Middle Aged; D013577:Syndrome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab